Small Molecules

15 May 2017 Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
15 May 2017 IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
13 May 2017 AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice (GCP) standards
13 May 2017 Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
11 May 2017 Orphazyme completes enrolment of patients for phase 3 clinical trial in Niemann-Pick type C disease
11 May 2017 Milestone Pharmaceuticals Announces Etripamil Phase 2 Clinical Program Success for the Treatment of Paroxysmal Supraventricular Tachycardia
11 May 2017 Peloton Therapeutics Initiates Patient Dosing in Phase 2 Study of PT2385 for von Hippel-Lindau Disease-Associated Kidney Cancer
11 May 2017 Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302
10 May 2017 Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292
10 May 2017 Abide Therapeutics Announces Dosing of First Subject in fMRI Imaging Study to Investigate Brain Activity Patterns Associated with ABX-1431
10 May 2017 Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma
09 May 2017 AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease
09 May 2017 Addex ADX71441 Demonstrates Preclinical Analgesic Effects
09 May 2017 PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections
08 May 2017 Embera NeuroTherapeutics Announces Positive Topline Data from Phase 1b Cocaine Interaction Study of EMB-001
08 May 2017 Rasna Therapeutics, Inc. Advances Development of a Novel Treatment for NPM1-mutated Acute Myeloid Leukemia
08 May 2017 Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Heavy Menstrual Bleeding and Uterine Fibroids at the Annual Meeting of the American Congress of Obstetricians and Gynecologists
08 May 2017 Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
07 May 2017 Norgine Presents New Post-hoc Data Analyses Highlighting the Efficacy of PLENVU for Bowel Cleansing at DDW
06 May 2017 Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint
06 May 2017 MT Pharma America Announces FDA Approval of RADICAVA™ (Edaravone), the First New Treatment Option for ALS in More Than 20 Years
05 May 2017 Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis
05 May 2017 Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor
05 May 2017 GENFIT: First patient enrolled in a phase 2 trial recruiting adults with Primary Biliary Cholangitis (PBC), a rare liver disease
04 May 2017 OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing